Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$76.44 USD

76.44
7,419,542

-0.11 (-0.14%)

Updated Sep 17, 2025 04:00 PM ET

Pre-Market: $76.77 +0.33 (0.43%) 8:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Will DexCom (DXCM) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, DexCom (DXCM) closed at $405.40, marking a +1.81% move from the previous day.

Zacks Equity Research

Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JKH

Zacks Equity Research

The Zacks Analyst Blog Highlights: Tesla, Fortinet, West Pharmaceutical Services, DexCom and Tractor Supply

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Tesla, Fortinet, West Pharmaceutical Services, DexCom and Tractor Supply

Zacks Equity Research

Here's Why You Should Retain Glaukos in Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Glaukos (GKOS) stock, thanks to solid prospects.

Tirthankar Chakraborty headshot

5 Best Stocks From 100 Days of Coronavirus

by Tirthankar Chakraborty

Here're five big stock winners from the first 100 days of the coronavirus pandemic that ravaged the global economy and shook the stock market.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Reckitt Benckiser, Henkel AG, DexCom, Tencent and Peloton Interactive

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Reckitt Benckiser, Henkel AG, DexCom, Tencent and Peloton Interactive

Trina Mukherjee headshot

3 MedTech Stocks to Watch Amid Coronavirus Catastrophe

by Trina Mukherjee

Let's keep a watch on three stocks that have displayed strong performance amid market turmoil led by the ongoing pandemic.

Zacks Equity Research

DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

DexCom (DXCM) closed the most recent trading day at $393, moving -1.44% from the previous trading session.

Urmimala Biswas headshot

Economic Recovery Debate Heats Up: 4 Sectors Holding Ground

by Urmimala Biswas

Here we discuss four sectors for which COVID-19 has opened up enormous growth prospects.

Sriparna Ghosal headshot

3 Diabetes Management Stocks in the Spotlight Amid Coronavirus

by Sriparna Ghosal

Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments

Zacks Equity Research

DexCom (DXCM) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, DexCom (DXCM) closed at $385.17, marking a +1.23% move from the previous day.

Zacks Equity Research

DexCom's (DXCM) G6 CGM System Gets CE Marking in Europe

by Zacks Equity Research

DexCom (DXCM) announces the receipt of CE Marking across Europe for its G6 CGM System.

Zacks Equity Research

ABIOMED Gets FDA Nod for First-in-Human Trial of Impella ECP

by Zacks Equity Research

This regulatory approval is expected to boost ABIOMED's (ABMD) Impella product line.

Zacks Equity Research

Here's Why You Should Retain AmerisourceBergen Stock Now

by Zacks Equity Research

Investor confidence is high on AmerisourceBergen (ABC) stock, thanks to solid prospects.

Zacks Equity Research

Here's Why You Should Retain Ecolab in Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Ecolab (ECL) stock, thanks to solid prospects.

Zacks Equity Research

Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JKH

Zacks Equity Research

ABIOMED's (ABMD) Impella RP Receives FDA's EUA Clearance

by Zacks Equity Research

This regulatory approval is expected to boost ABIOMED's (ABMD) Impella product portfolio.

Sanghamitra Saha headshot

Do You Always Look for Earnings Beat? 5 Sectors to Play

by Sanghamitra Saha

These sectors came up with stellar earnings beat in the recent cycle. Investors can play the associated stocks that delivered an earnings surprise.

Zacks Equity Research

Here's Why You Should Add Accuray to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Accuray (ARAY) stock, thanks to solid prospects.

Zacks Equity Research

Here's Why You Should Add DexCom (DXCM) to Your Portfolio

by Zacks Equity Research

DexCom (DXCM) continues to gain traction from strong international presence and robust product portfolio.

Zacks Equity Research

DexCom (DXCM) Up 4.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Retain Inogen in Your Portfolio Now

by Zacks Equity Research

Investor confidence is high in Inogen (INGN) stock, thanks to solid prospects.

Zacks Equity Research

Varian (VAR) Unveils New Features for Noona Software

by Zacks Equity Research

This development, which is in response to the challenges brought on by the pandemic, is expected to boost Varian's (VAR) Oncology segment.

Sreoshi Bera headshot

5 Health Care Stocks to Bet on as Coronavirus Woes Linger

by Sreoshi Bera

The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.